Description
Elsevier Two-Point Boundary Value Problems Lower And Upper Solutions Volume 205 by C. de Coster , P. Habets
This book introduces the method of lower and upper solutions for ordinary differential equations. This method is known to be both easy and powerful to solve second order boundary value problems. Besides an extensive introduction to the method, the first half of the book describes some recent and more involved results on this subject. These concern the combined use of the method with degree theory, with variational methods and positive operators. The second half of the book concerns applications. This part exemplifies the method and provides the reader with a fairly large introduction to the problematic of boundary value problems. Although the book concerns mainly ordinary differential equations, some attention is given to other settings such as partial differential equations or functional differential equations. A detailed history of the problem is described in the introduction. PrefaceList of contributorsPart I: Perspective on immunological mechanisms underlying adjuvant activityChapter 1: Unraveling aEUROoethe immunologist's dirty little secretaEURO Part II: Host-derived immunopotentiatorsChapter 2: Dendritic cells as targets and tools in vaccinesChapter 3: Host-derived molecules as adjuvantsPart III: Natural and synthetic immunopotentiatorsChapter 4: Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvantsChapter 5: CpG oligodeoxynucleotides as vaccine adjuvantsChapter 6: Toll-like receptor 4 agonists as vaccine adjuvantsChapter 7: Immunomodulatory adjuvants from Quillaja saponariaPart IV: Particulate immunopotentiators and delivery systemsChapter 8: Microparticles as vaccine delivery systemsChapter 9: MF59: a safe and potent adjuvant for human useChapter 10: Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum saltChapter 11: Virosomes for vaccine deliveryChapter 12: The ISCOMATRIXa"c adjuvantChapter 13: Mineral adjuvantsPart V: Mucosal/nonparenteral adjuvantsChapter 14: Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxinChapter 15: Transcutaneous immunization using the heat-labile enterotoxin of E. coli as an adjuvantPart VI: Th-1/CTL adjuvantsChapter 16: T cell adjuvants and novel strategies for their identificationPart VII: Adjuvants in noninfectious disease vaccinesChapter 17: Vaccination to treat noninfectious diseases: surveying the opportunitiesPart VIII: Clinical practiceChapter 18: Clinical evaluation of adjuvantsChapter 19: Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccinesIndex